

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cynata Therapeutics Limited</b>
<b>ABN</b>	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Geoffrey Brooke</b>
<b>Date of last notice</b>	<b>1 June 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect 3. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary 3. Dalhigh Pty Ltd <Dalhigh Investments A/C> - director and beneficiary
<b>Date of change</b>	20 November 2023
<b>No. of securities held prior to change</b>	1. 300,000 unlisted options exercisable at \$2.11, exp 16/11/2024 2,000,000 unlisted options exercisable at \$0.97, exp 29/11/2025 2. 117,809 ordinary shares 3. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025
<b>Class</b>	Unlisted options exercisable at \$0.185 exp 20/11/2028
<b>Number acquired</b>	1. 500,000 unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Number disposed</b>	-

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration includes brokerage/gst</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 300,000 unlisted options exercisable at \$2.11, exp 16/11/2024</li> <li>2,000,000 unlisted options exercisable at \$0.97, exp 29/11/2025</li> <li>500,000 unlisted options exercisable at \$0.185, exp 20/11/2028</li> <li>2. 257,343 ordinary shares</li> <li>69,767 listed options exercisable at \$0.30 exp 1/4/2025</li> <li>3. Nil</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of director options following shareholder approval at the AGM held on 13 November 2023.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cynata Therapeutics Limited</b>
<b>ABN</b>	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Kilian Kelly</b>
<b>Date of last notice</b>	<b>3 July 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Tamara Kelly (Wife)
<b>Date of change</b>	20 November 2023
<b>No. of securities held prior to change</b>	1. 477,373 ordinary shares 1,000,000 unlisted options exercisable at \$0.97, exp 18/08/2024 2,000,000 unlisted options exercisable at \$0.176, exp 30/06/2028 2. 48,135 ordinary shares 15,748 listed options exercisable at \$0.30, exp 1/4/2025
<b>Class</b>	Unlisted options exercisable at \$0.185 exp 20/11/2028
<b>Number acquired</b>	2. 750,000 unlisted options exercisable at \$0.185 exp 20/11/2028
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 477,373 ordinary shares 1,000,000 unlisted options exercisable at \$0.97, exp 18/08/2024 2,000,000 unlisted options exercisable at \$0.176, exp 30/06/2028</li> <li>2. 48,135 ordinary shares 15,748 listed options exercisable at \$0.30, exp 1/4/2025 750,000 unlisted options exercisable at \$0.185, exp 20/11/2028</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of director options following shareholder approval at the AGM held on 13 November 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cynata Therapeutics Limited</b>
<b>ABN</b>	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Darryl Maher</b>
<b>Date of last notice</b>	<b>1 June 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	20 November 2023
<b>No. of securities held prior to change</b>	50,000 ordinary shares 25,000 listed options exercisable at \$0.30 exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025
<b>Class</b>	Unlisted options exercisable at \$0.185 exp 20/11/2028
<b>Number acquired</b>	220,000 unlisted options exercisable at \$0.185 exp 20/11/2028
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	50,000 ordinary shares 25,000 listed options exercisable at \$0.30, exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 220,000 unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of director options following shareholder approval at the AGM held on 13 November 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cynata Therapeutics Limited</b>
<b>ABN</b>	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Ms Janine Rolfe</b>
<b>Date of last notice</b>	<b>1 June 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Rolfe Pty Ltd <J&R Rolfe Superannuation Fund> - director of trustee and beneficiary of fund
<b>Date of change</b>	20 November 2023
<b>No. of securities held prior to change</b>	1. 300,000 unlisted options exercisable at \$0.51, exp 23/11/2027 2. 116,279 ordinary shares 58,140 listed options exercisable at \$0.30 exp 1/4/2025
<b>Class</b>	Unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Number acquired</b>	1. 220,000 unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 300,000 unlisted options exercisable at \$0.51, exp 23/11/2027 220,000 unlisted options exercisable at \$0.185, exp 20/11/2028</li> <li>2. 116,279 ordinary shares 58,140 listed options exercisable at \$0.30 exp 1/4/2025</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of director options following shareholder approval at the AGM held on 13 November 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Cynata Therapeutics Limited</b>
<b>ABN</b>	98 104 037 372

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr Paul K Wotton</b>
<b>Date of last notice</b>	<b>1 June 2023</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Citicorp Nominees Pty Limited (beneficial interest)
<b>Date of change</b>	20 November 2023
<b>No. of securities held prior to change</b>	1. 139,534 ordinary shares 69,767 listed options exercisable at \$0.30 exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 2. 175,775 ordinary shares
<b>Class</b>	Unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Number acquired</b>	1. 220,000 unlisted options exercisable at \$0.185, exp 20/11/2028
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 69,767 listed options exercisable at \$0.30 exp 1/4/2025 300,000 unlisted options exercisable at \$0.97, exp 29/11/2025 220,000 unlisted options exercisable at \$0.185, exp 20/11/2028</li> <li>2. 315,309 ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of director options following shareholder approval at the AGM held on 13 November 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.